(Q48234878)

English

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

scientific article published on 16 January 2018

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/29338080

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/29338080

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

Eileen M. O'Reilly

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Zsofia K. Stadler

5

object named as

Zsofia K Stadler

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Jonathan W Lee

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marinela Capanu

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Malcolm J Moore

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Neesha Dhani

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hedy L Kindler

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hayley Estrella

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hannah Maynard

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Talia Golan

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Amiel Segal

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Erin E Salo-Mullen

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Kenneth H Yu

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Andrew S Epstein

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Michal Segal

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Robin Brenner

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Richard K Do

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Alice P Chen

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Laura H Tang

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

David P Kelsen

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

0 references

publication date

16 January 2018

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/29338080

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

124

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1374-1382

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

BRCA1 and pancreatic cancer: pedigree findings and their causal relationships

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Myelodysplastic syndrome after cisplatin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31218

21 January 2018

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5867226

2 November 2018

BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5867226

2 November 2018

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29338080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.31218

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

release_z5cvnbczlfa2hcrytnrnyop3ma

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29338080%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48234878&oldid=2192317811"